Related Experiment Videos
N of 1 randomized trials for investigating new drugs
G H Guyatt1, A Heyting, R Jaeschke
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Abstract:
Presently, in the process of new drug development, large sample parallel group randomized trials are often begun without the detailed knowledge of optimal dose, most responsive patient group, and optimal outcomes which would be desirable. We propose that randomized trials in individual subjects (N of 1 RCTs) could be used to elucidate these issues at an early stage of drug development. In appropriate conditions N of 1 RCTs can be used to define the rapidity with which a drug begins and ceases its clinical action, the likely range of the optimal drug dose, and the optimal outcomes on which subsequent trials should focus. N of 1 RCTs can also generate initial estimates of the proportion of patients who respond to a new agent and for determining sample size, inclusion criteria, and dosage regimen(s) for subsequent parallel group trials. We provide an example of 14 N of 1 RCTs of amitriptyline in fibrositis that illustrate the ways in which N of 1 RCTs can elucidate these issues. The multiple uses of N of 1 RCTs suggest that the method has immense potential for use in the early phases of drug development programs.
Insights
Randomized trials in individual subjects (N-of-1 RCTs) can optimize early drug development by identifying ideal dosages and patient groups. This method enhances the efficiency and focus of subsequent large-scale clinical trials.
Area of Science:
- Pharmacology
- Clinical Trials
- Drug Development
Background:
- Large-scale randomized trials often commence without optimal dose or patient group knowledge.
- Early-stage drug development requires efficient methods to define key trial parameters.
Purpose of the Study:
- To propose and illustrate the utility of N-of-1 randomized controlled trials (RCTs) in early drug development.
- To demonstrate how N-of-1 RCTs can inform dose selection, patient stratification, and outcome measures.
Main Methods:
- Utilized N-of-1 RCTs to investigate drug action kinetics, optimal dosage ranges, and response variability.
- Applied N-of-1 RCTs to estimate treatment effects and inform the design of parallel group trials.
- Presented a case study of 14 N-of-1 RCTs for amitriptyline in fibrositis.
Main Results:
- N-of-1 RCTs can determine the speed of drug onset and offset, optimal dose ranges, and appropriate outcome measures.
- This method provides initial estimates of patient response proportions for sample size calculations.
- N-of-1 RCTs facilitate the determination of inclusion criteria and dosage regimens for larger trials.
Conclusions:
- N-of-1 RCTs offer a powerful approach for early-phase drug development.
- The method enhances the efficiency and precision of designing subsequent clinical trials.
- N-of-1 RCTs have significant potential to refine drug development programs.